Induction Chemotherapy Versus Upfront Chemoradiation for Locoregionally Advanced of Head and Neck Cancer

Document Type : Original Article


Department of Clinical oncology, Faculty of Medicine, Sohag University, Sohag, Egypt.


Aim of the work: evaluatethe response rate , acute and late adverse effects of induction chemotherapy followed by concurrent chemoradiotherapy  . secondary end points include overall survival and progression free survival in patients with locoregionally advanced of  Squamous cell head and neck cancer (HNSCC) .
Patients and Method: A retrospective study of 48  patientswith pathologically proven Stage III-IVB ofSquamous cell head and neck cancer (HNSCC) who presented to the clinical oncology department, sohag University hospital fromJanuary 2010  to March 2017. Patients were treated with induction chemotherapy followed by concurrent chemoradiation therapy or initially  concurrentchemoradiation therapy. This study was conducted by hand search in the files and radiotherapy sheetof these patients.
Results: Fourty_eight  patients with locally advanced head and neck squamous cell carcinoma were included in this study. It was conducted at the Clinical Oncology and Nuclear Medicine Department, Sohag Faculty of Medicine .Of the 48 identified patients, 20  patients received IC followed with CCRT and 28    patients received only  CCRT. Therewas no statistically significant difference between both groups as regards response at 24 , 36 and 45 months.In group of CCRT , 18  patients had CR to primary treatment ,  7 Patients had PR and 7 Patients had Progressive disease    . Ingroup of IC, 12  patients had CR ,6  patients had PR and one patient have Progressive disease . Acute skin reactions andacute mucositiswere experienced by  all patients .There was no statistically significant difference between the two groups as regards xerostomia and Chronic skin and subcutaneous toxicity .
Conclusion:Our findings did not show that adding induction chemotherapy to chemoradiotherapy was better than concurrent chemoradiotherapy alone in locally advanced head and neck cancer , so the latter remains standard therapy in patients with LAHNC .

1-   Cohen EE, Karrison T, Kocherginsky M, Huang CH, Agulnik M, Mittal BB, Yunus F, Samant S, Brockstein B, Raez LE, Mehra R, Kumar P, Ondrey FG, Seiwert TY, Villaflor VM, Haraf DJ, EE V (2012) DeCIDE: a phase III randomized trial of docetaxel (D), cisplatin (P), 5- fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advancedsquamous cell carcinoma of the head and neck (SCCHN). J ClinOncol, 2012 ASCO annual meeting abstracts, vol 30, No 15_suppl (May 20 Suppl), 5500
2-   C.M.L. Driessen , J.P. de Boer et al (2016) . Induction chemotherapy with docetaxel/cisplatin/ 5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study 
3-   David J, Adelstein and Michael Le Blanc ; (2006) Does Induction Chemotherapy Have a Role in the  Management of  Locoregionally Advanced Squamous Cell  Head and Neck Cancer? , JCO ; 24  (17) 2624 - 2627 .
4-   -Gregoire V, Lefebvre JL, Licitra L, Felip E, Group E-E-EGW (2010) Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v184–v186.
5-   Jemal  A, Bray F, Center MM; et al , (2011),. Global cancer statistics CA Cancer J Clin; 61(2):69-90.
6-   Marshall  Posnera and Jan B. Vermorken ; (2008) , Induction Therapy in the Modern Era of Combined-Modality Therapy for Locally Advanced Head and Neck Cancer , SeminOncol 35:221-228 .
7-   Paccagnella A, Ghi MG, Loreggian L, et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: phase II randomizedstudy. Ann Oncol 2010; 21: 1515–22.
8-   Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, ViroglioRdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI, Group TAXS (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357(17):1705–1715.
9-   Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL, Group ETS (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357(17):1695–1704.